Merck touts PhIII Keytruda data in frontline endometrial cancer
In a boost to Merck’s efforts of moving blockbuster drug Keytruda to earlier lines of treatment, Phase III data in endometrial cancer patients show significant improvements in reducing the risk of disease progression or death, the company revealed today.
Merck highlighted how Keytruda helped a broad swath of patients, regardless of their mismatch repair status — a marker of how well cancer cells can repair erroneous DNA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.